Skip to search formSkip to main contentSkip to account menu

lexatumumab

A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2… 
National Institutes of Health

Related topics

Related topics

8 relations
IMC 1121BInhibition of Cell ProliferationPositive Regulation of ApoptosisTNFRSF10B protein, human

Narrower (1)

LY3009806

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Therapeutic targeting of the TNF superfamily: a promising treatment for advanced endometrial adenocarcinoma.
2012
2012
Delineation of apoptotic genes for synergistic apoptosis of lexatumumab and anthracyclines in human renal cell carcinoma cells by polymerase chain reaction array
Lexatumumab, a human agonistic monoclonal antibody against tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor… 
2012
2012
Abstract 2758: Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: Evidence for the role of C-Jun N-terminal kinase activation
Discovery of the molecular targets of chemotherapeutic medicines and their chemical footprints can validate and improve the use… 
2011
2011
Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction
Tumor growth is often associated with insufficient apoptosis. The Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand… 
2010
2010
Lexatumumab: Results of a phase I trial in pediatric patients with advanced solid tumors.
9500 Background: Lexatumumab is an agonist, fully-human monoclonal antibody against TNF-Related Apoptosis Inducing Ligand… 
2010
2010
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.
Resistance of tumors to cell death signals poses a complex clinical problem. In the present study, we have explored the capacity… 
2007
2007
A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
2007
2007
Bortezomib Sensitizes Non–Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2
Non–Hodgkin's lymphoma (NHL) is an increasingly common disease that, despite advances in antibody-targeted therapy, still… 
2007
2007
Low-Dose 12-O-Tetradecanoylphorbol-13-Acetate Enhances Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis in Prostate Cancer Cells
Purpose: Previously, we have shown that c-Fos/activator protein-1 (AP-1) promotes tumor necrosis factor (TNF)–related apoptosis… 
2007
2007
Rituximab Sensitizes TRAIL-Resistant B-NHL Lines to Apoptosis by Both TRAIL and Fully Humanized Antibodies Targeting TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumumab).
Clinical trials are currently in progress to evaluate the therapeutic efficacy of recombinant human TRAIL and fully humanized… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)